Tools
Tools
Younis, Tallal and Skedgel, Chris 
ORCID: https://orcid.org/0000-0003-4989-8846
(2008)
Is trastuzumab a cost-effective treatment for breast cancer?
Expert Review of Pharmacoeconomics & Outcomes Research, 8 (5).
pp. 433-442.
ISSN 1473-7167
Abstract
Trastuzumab is a recombinant humanized monoclonal antibody that is currently approved for the treatment of HER2-neu-positive breast cancer. From a clinical perspective, it is an effective treatment with a relatively favorable benefit/risk profile. From an economic perspective, trastuzumab is an expensive treatment that is associated with high drug acquisition cost. Overall, it appears to provide reasonable 'value for money' (i.e., is cost-effective), especially in the adjuvant as opposed to the palliative setting. Trastuzumab's cost-effectiveness appears to be driven primarily by trastuzumab costs and the magnitude of benefit derived. Longer follow-up of clinical trials is, therefore, required to better estimate the long-term benefits associated with adjuvant trastuzumab, and its true cost-effectiveness in the treatment of HER2-neu-positive breast cancer.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | breast cancer,clinical trial,cost-effectiveness,cost-utility,trastuzumab,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023) |
| Depositing User: | Pure Connector |
| Date Deposited: | 04 Feb 2015 12:34 |
| Last Modified: | 21 Oct 2022 00:29 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/51938 |
| DOI: | 10.1586/14737167.8.5.433 |
Actions (login required)
 |
View Item |